Skip to main content

Rare Disease vs Dermatology — Deal Terms Comparison

Rare Disease Median Upfront
$285M
Total: $1.6B
Dermatology Median Upfront
$393M
Total: $2.1B
Rare Disease Royalties
7.8%-15.6%
Tiered to 19.6%
Dermatology Royalties
6.5%-13.1%
Tiered to 17.1%

Market Analysis

Rare Disease and Dermatology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 rare disease deals carry a median total deal value of $1.6B with $285M upfront, compared to $2.1B total value and $393M upfront for dermatology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do rare disease and dermatology deal terms compare?
Rare Disease Phase 2 deals average $1.6B total value ($285M upfront), while Dermatology deals average $2.1B ($393M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating